Minimally invasive screening methods offer a more accessible, cost-effective way to detect Barrett’s esophagus early and help prevent esophageal cancer.

Esophageal cancer is an aggressive, deadly cancer often caught in advanced stages. The likelihood of surviving for five years ...

Lucid Diagnostics’ core strength lies in its EsoGuard/EsoCheck offerings, which are positioned to potentially become the new standard for BE-EAC screening. The company operates in a market with ...

Lucid Diagnostics’ core strength lies in its EsoGuard/EsoCheck offerings, which are positioned to potentially become the new standard for BE-EAC screening. The company operates in a market with ...

CEO Lishan Aklog stated that Lucid Diagnostics is “better positioned than ever to capitalize on EsoGuard’s really huge clinical and market opportunity,” emphasizing recent progress including securing ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that ...

The father of four is also trying to get fire departments nationwide to offer Lucid Diagnostics’ EsoGuard DNA test to detect abnormal esophageal cells before they progress to cancer.

Firefighters have a 62% higher likelihood of getting esophageal cancer because of the occupational risk from exposure to ...

CEO Lishan Aklog stated that Lucid Diagnostics is “better positioned than ever to capitalize on EsoGuard’s really huge clinical and market opportunity,” emphasizing recent progress including ...

Processed 3,034 EsoGuard ® tests and recognized revenue of $0.8 million in 1Q25 Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million ...